North Central Cancer Treatment Group

Known as: NCCTG 
A national clinical research group sponsored by the NCI. The research base for NCCTG is located at Mayo Clinic in Rochester, Minn. NCCTG consists of… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
PURPOSE To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
PURPOSE Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
PURPOSE Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.
PURPOSE Fatigue is one of the most common symptoms experienced by patients with cancer. This trial was developed to evaluate the… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
PURPOSE To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
Combined deletion of chromosomes 1p and 19q is associated with improved prognosis and responsiveness to therapy in patients with… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2006
Review
2006
Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Up to one fourth of women diagnosed with early breast cancer (EBC) have tumors that are human epidermal growth factor receptor 2… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2005
2005
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
BACKGROUND PS-341 is a proteasome inhibitor with preclinical activity in pancreatic cancer tumor models and synergistic activity… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
PURPOSE To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American… (More)
Is this relevant?
Highly Cited
1989
Highly Cited
1989
A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study.
The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five… (More)
Is this relevant?